Current Funding
2021 – 2026 Principal Investigator. Dissecting the origins and microenvironment of replication repair deficient hypermutant gliomas for novel immune based therapies. Canadian Institute of Health Research (CIHR). Principal Investigator: Tabori, U. Co- investigators: Dirks, P., Hawkins, C., Gallo, M., Angers, S. 1,300,000.00 CAD.
2021 – 2023 Prinicipal Investigator. Molecular Classification of Primary CNS Tumors in Adolescents and Young Adults. C17 Research Network. Principal Investigator: Tabori, U. Co-applicants: Hawkins, C., Bennett, J., Lim-Fat, MJ., Das, S. 72,000 CAD.
2020 – 2023 Principal Investiagor. Detection and Prevention of Hypermutant Glioma in Children and Young Adults. Canadian Cancer Society/Canadian Institute of Health Research (CCS/CIHR). Spark Grant. Principal Investigator: Tabori, U. 150,000 CAD.
2020 – 2023 Co-applicant. Early Detection and Novel Stratification of Pediatric Low-Grade Gliomas by MRI-based Artificial Intelligence. Canadian Cancer Society/Canadian Institute of Health Research (CCS/CIHR). Spark Grant. Principal Investigator: Khalvati, F. Co-applicants: Tabori,U.150,000 CAD.
2020 – 2023 Principal Investigator. Landscape of Somatic and Inherited Replication Repair Deficiency towards a Childhood Cancer Vaccine. National Cancer Institute Community Oncology. Research Program Grant. Prinicipal Investigator: Tabori, U. 1,200,000 USD.
2019 – 2023 Principal Investigator. Clinical translation of novel immune-based combination therapies for Paediatric Hypermutant cancers. Stand Up To Cancer (SU2C), Pediatric Catalyst Research Grant. Principal Investigator: Tabori, U. 4,000,000.00 CAD.
2019 – 2022 Co-Applicant. NanoStrng Couner Vantage 3D platform-based complementary diagnositic tests for precision medicine in pediatric cancers. Genome Canada. Principal Investigator: Hawkins C. Co-applicants: Somers G., Tabori U. 3,978,462 CAD.
2019 – 2022 Principal Investigator. Biological and pre-clinical studies to enable TIL therapy clinical trial in pediatric hypermutant cancers. V-foundation USA. Principal Investigator: Tabori, U. 600,000 USD.
2018 – 2023 Principal Investigator. Biological and translational implications of replication repair deficiency and hyper mutation in human cancer. Canadian Institute of Health Research (CIHR). Principal Investigator: Tabori, U. 1,250,000.00 CAD.
2018 – 2023 Co-Applicant. Molecular based approach to improve outcome for children and young adults with low grade glioma. Canadian Institute of Health Research (CIHR). Operating Grant. Principal Investigator: Hawkins, C. Collaborators: Tabori, U. 1,000,000 CAD.
Completed Funding – within the last 6 years
2020 – 2021 Principal Investigator. Alteration of mutagenic gut microbiome for cancer prevention. Pitblado Discovery Grant. Principal Investigator: Tabori, U. 60,000 CAD.
2019 – 2021 Principal Investigator. Catalyzing the University of Toronto as a Global Epicenter for Translational Research and Training. Connaught Global Translational Award. Principal Investigator: Tabori, U.Collaborators: Gotlieb A., Ferenbok J. 200,000 CAD.
2019 Principal Investigator. A comprehensive clinical and molecular characterization of low grade gliomas in adolescents and young adults. B.R.A.I.N Child. Principal Investigator: Tabori, U. Canada. 25,000 CAD.
2019 Co-Principal Investigator. A Phase 2 study of Trametinib for patients with pedriatic glioma or plexiform neurofibroma with refactory tumor and activation of the MAPK/ERK pathway. Canadian Institute of Health Research (CIHR). Principal Investigator: Perrault, S., Tabori, U. 1,500,000 CAD.
2017 – 2019 Principal Investigator. Combined approaches by immune checkpoint inhibition for Hypermutant cancers. American Association for Cancer Research (AACR) and Bristol-Myers Squibb (BMS). Stand Up To Cancer (SU2C) Catalyst research grant. Principal Investigator: Tabori, U. 4,000,000 USD.
2017 Principal Investigator. Minimally invasive diagnostics for therapeutic and disease monitoring in childhood Cancer. Pitbaldo Cancer center grant. Principal Investigator: Tabori, U. 50,000 CAD.
2016 – 2020 Principal Investigator. Developmental and predictive companion biomarkers and theraputic monitoring for hypermutant cancers to immune checkpoint inhibition. BioCanRx. Principal Investigator: Tabori, U. 400,000 CAD.
2016 – 2019 Co-Applicant. Clinical development and translation of genomics-driven pediatric cancer diagnostics using Nano String technology. Genome Canada. Principal Investigator: Hawkins, C. Collaborators: Tabori, U. 600,000 CAD.
2016 – 2018 Principal Investigator. Direct translation of genetic and Immunophenotypic characterization for clinical companion diagnostic and therapeutic monitoring of mismatch repair deficient Ultra-Hypermutant Paediatric cancers to immune checkpoint inhibition. BioCanRX, Enabling Studies program. Principal Investigator: Tabori, U. 750,000 CAD.
2016 – 2017 Principal Investigator. Universal novel classification of childhood low grade gliomas using clinic-pathological and biological methods. The PLGA foundation USA. Principal Investigator: Tabori, U. 50,000 CAD.
2016 – 2017 Co-Applicant. Ultra-sensitive minimally invasive diagnostics for therapeutic and disease monitoring in childhood brain tumors. Ontario Centre of Excellence, P.O.P Grant. Principal investigator: Hawkins, C. Collaborators: Tabori, U. 140,000 CAD.
2015 – 2020 Principal Investigator. Targeting the telomere maintenance pathway for cancer diagnostics and therapeutics. Canadian Cancer Research Society. Impact Grant. Principal Investigator: Tabori, U. Collaborators: Kelly, S., Dirks, P., Bristow, R., Shlien, A., Castelo-Branco, P., Mai, S. 1,250,000 CAD.
2015 – 2018 Principal Investigator. Translating genomic discoveries to cure Ultra-Hypermutant mismatch repair deficient brain tumors. Canadian Institute of Health Research (CIHR), Israel- Canada Joint Research Program. Principal Investigator: Tabori, U. 1,300,000 CAD.
2015 – 2016 Principal Investigator. Long term clinical implication of pediatric low grade glioma molecular subgroups (part 2). Making Headway Foundation, USA. Principal Investigator: Tabori, U. 25,000 USD.
2015 – 2016 Principal Investigator. Establishment of a mismatch repair zebrafish brain tumor model. B.R.A.I.N. Child. Principal Investigator: Tabori, U. 25,000 CAD.
2014 – 2019 Principal Investigator. Novel implications of THOR hyper methylation in telomere maintenance and glioma genesis. Canadian Institute of Health Research (CIHR). Principal Investigator: Tabori, U. 990,000 CAD.
2014 – 2016 Principal Investigator. Utilization of THOR hyper methylation for stratification and noninvasive detection of cancer. Canadian Cancer Research Society. Innovation grant. Principal Investigator: Tabori, U. 200,000 CAD.
2012 – 2016 Principal Investigator. Clinical and biological implications of Monoallelic gene expression in pediatric malignant brain tumors. Canadian Institute of Health Research (CIHR). Principal Investigator: Tabori, U., Michael, T. 573,543 CAD.